ARNA Projected Dividend Yield
Arena Pharmaceuticals Inc ( NASDAQ : ARNA )Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics to patients globally. Co.'s clinical programs include: etrasimod (APD334), which Co. is evaluating in ulcerative colitis, and Crohn's disease, as well as a program for atopic dermatitis; olorinab (APD371), which is is being evaluated for a range of visceral pain conditions associated with gastrointestinal diseases and for treatment of abdominal pain associated with irritable bowel syndrome; APD418, which is being evaluated in a trial for acute heart failure; and Temanogrel, a compound in its cardiovascular therapeutic area. 20 YEAR PERFORMANCE RESULTS |
ARNA Dividend History Detail ARNA Dividend News ARNA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |